BIOPHYTIS SA-ADR (BPTS)

US09076G2030 - ADR

8.22  -1.48 (-15.28%)

After market: 7.92 -0.3 (-3.65%)

Fundamental Rating

0

Taking everything into account, BPTS scores 0 out of 10 in our fundamental rating. BPTS was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of BPTS have multiple concerns. BPTS has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

BPTS had negative earnings in the past year.
BPTS had a negative operating cash flow in the past year.
BPTS had negative earnings in each of the past 5 years.
In the past 5 years BPTS always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -134.02%, BPTS is not doing good in the industry: 84.47% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -134.02%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BPTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

1

2. Health

2.1 Basic Checks

There is no outstanding debt for BPTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

BPTS has an Altman-Z score of -2.84. This is a bad value and indicates that BPTS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BPTS (-2.84) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.84
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

BPTS has a Current Ratio of 0.81. This is a bad value and indicates that BPTS is not financially healthy enough and could expect problems in meeting its short term obligations.
BPTS has a Current ratio of 0.81. This is amonst the worse of the industry: BPTS underperforms 91.64% of its industry peers.
A Quick Ratio of 0.81 indicates that BPTS may have some problems paying its short term obligations.
BPTS's Quick ratio of 0.81 is on the low side compared to the rest of the industry. BPTS is outperformed by 91.13% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.81

0

3. Growth

3.1 Past

BPTS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.64%, which is quite impressive.
EPS 1Y (TTM)63.64%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

BPTS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-133.33%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

BPTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BPTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for BPTS!.
Industry RankSector Rank
Dividend Yield N/A

BIOPHYTIS SA-ADR

NASDAQ:BPTS (4/25/2024, 7:00:01 PM)

After market: 7.92 -0.3 (-3.65%)

8.22

-1.48 (-15.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap94.20M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -134.02%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.81
Quick Ratio 0.81
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)63.64%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-133.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y